Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration

Simple item page
dc.contributor.authorOrnbjerg, LM
dc.contributor.authorLinde, L
dc.contributor.authorGeorgiadis, S
dc.contributor.authorRasmussen, SH
dc.contributor.authorLindström, U
dc.contributor.authorAskling, J
dc.contributor.authorMichelsen, B
dc.contributor.authorDi Giuseppe, D
dc.contributor.authorWallman, JK
dc.contributor.authorPavelka, K
dc.contributor.authorZávada, J
dc.contributor.authorNissen, MJ
dc.contributor.authorJones, GT
dc.contributor.authorRelas, H
dc.contributor.authorPirilä, L
dc.contributor.authorTomsic, M
dc.contributor.authorRotar, Z
dc.contributor.authorGeirsson, AJ
dc.contributor.authorGudbjornsson, B
dc.contributor.authorKristianslund, EK
dc.contributor.authorHorst-Bruinsma, IV
dc.contributor.authorLoft, AG
dc.contributor.authorLaas, K
dc.contributor.authorIannone, F
dc.contributor.authorCorrado, A
dc.contributor.authorCiurea, A
dc.contributor.authorSantos, MJ
dc.contributor.authorSantos, H
dc.contributor.authorCodreanu, C
dc.contributor.authorAkkoc, N
dc.contributor.authorGunduz, OS
dc.contributor.authorGlintborg, B
dc.contributor.authorOstergaard, M
dc.contributor.authorHetland, ML
dc.date.accessioned2024-07-18T12:08:40Z
dc.date.available2024-07-18T12:08:40Z
dc.description.abstractObjectives: In patients with axial spondyloarthritis (axSpA) initiating their first tumor necrosis factor alpha-inhibitor (TNFi), we aimed to identify common baseline predictors of Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) inactive disease (primary objective) and clinically important improvement (CII) at 6 months, and drug retention at 12-months across 15 European registries. Methods: Baseline demographic and clinical characteristics were collected. Outcomes were investigated per registry and in pooled data using logistic regression analyses on multiply imputed data. Results: The consistency of baseline predictors in individual registries justified pooling the data. In the pooled dataset (n = 21,196), the 6-month rates for ASDAS inactive disease and ASDAS CII were 26% and 51%, and the 12-month drug retention rate 65% in patients with available data (n = 9,845, n = 6,948 and n = 21,196, respectively). Nine common baseline predictors of ASDAS inactive disease, ASDAS CII and 12-month drug retention were identified, and the odds ratios (95%-confidence interval) for ASDAS inactive disease were: age, per year: 0.97 (0.97-0.98), men vs. women: 1.88 (1.60-2.22), current vs. non-smoking: 0.76 (0.63-0.91), HLA-B27 positive vs. negative: 1.51 (1.20-1.91), TNF start year 2015-2018 vs. 2009-2014: 1.24 (1.06-1.45), CRP > 10 vs. <= 10 mg/l: 1.49 (1.25-1.77), one unit increase in health assessment questionnaire (HAQ): 0.77 (0.58-1.03), one-millimeter (mm) increase in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) fatigue and spinal pain: 0.99 (0.99-1.00) and 0.99 (0.99-1.99), respectively Conclusion: Common baseline predictors of treatment response and adherence to TNFi could be identified across data from 15 European registries, indicating that they may be universal across different axSpA populations.
dc.identifier.issn0049-0172
dc.identifier.other1532-866X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11034
dc.language.isoEnglish
dc.publisherW B SAUNDERS CO-ELSEVIER INC
dc.subjectACTIVITY SCORE ASDAS
dc.subjectANKYLOSING-SPONDYLITIS
dc.subjectPSORIATIC-ARTHRITIS
dc.subjectTREATMENT RESPONSE
dc.subjectALPHA DRUGS
dc.subjectREMISSION
dc.subjectCONTINUATION
dc.subjectTHERAPY
dc.titlePredictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu